Instrument Inactif

Communiqués Atrinsic, Inc. Other OTC

Actions

US04964C2089

Cours en clôture Other OTC
- ^USD	-

20/08	Protagenic Therapeutics reçoit un avis favorable de la FDA pour une nouvelle demande d'IND concernant le PT00114 dans le trouble de l'anxiété généralisée	CI
19/08	Protagenic Therapeutics, Inc. publie ses résultats pour le premier trimestre clos le 30 juin 2026	CI

Communiqués

20/08	Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder	AQ
14/08	Protagenic Therapeutics : Annual Report for Fiscal Year Ending March 31, 2026 (Form 10-K)	PU
30/06	Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model	AQ
19/05	Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner	AQ
23/04	Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114	AQ
17/03	Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114	AQ
09/03	Protagenic Therapeutics : Quarterly Report for Quarter Ending December 31, 2025 (Form 10-Q)	PU
25/08/25	Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders	AQ
30/07/25	Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates	AQ
22/05/25	Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity	AQ
29/04/25	Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split	AQ
06/11/24	Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million	AQ
05/11/24	Protagenic Therapeutics : Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million Form 8 K	PU
30/10/24	Protagenic Therapeutics : Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million Form 8 K	PU
23/05/24	Protagenic Therapeutics Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial	AQ
21/03/24	Protagenic Therapeutics, Inc.	AQ
14/02/24	Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders	AQ
31/03/23	PROTAGENIC THERAPEUTICS, INC.NEW Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
22/03/23	PROTAGENIC THERAPEUTICS, INC.NEW : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
29/11/22	PROTAGENIC THERAPEUTICS, INC.NEW : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	AQ
14/11/22	PROTAGENIC THERAPEUTICS, INC.NEW Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	AQ
02/09/22	PROTAGENIC THERAPEUTICS, INC.NEW : Other Events (form 8-K)	AQ
11/08/22	PROTAGENIC THERAPEUTICS, INC.NEW Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	AQ
29/06/22	PROTAGENIC THERAPEUTICS, INC.NEW : Other Events (form 8-K)	AQ
13/05/22	PROTAGENIC THERAPEUTICS, INC.NEW Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	AQ